Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza
Welcome,         Profile    Billing    Logout  
 16 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cavanna, Luigi
OINC, NCT04480268: PAXG Out in the Country

Recruiting
4
175
Europe
PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
IRCCS San Raffaele
Pancreatic Ductal Adenocarcinoma
01/22
01/26
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
ABIGAIL, NCT04603183 / 2020-001648-24: ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Active, not recruiting
2
162
Europe
Abemaciclib, Verzenios, Paclitaxel, Paclitaxel Teva, Letrozole, Fulvestrant
MedSIR, Eli Lilly and Company
Breast Cancer Metastatic
06/24
06/25
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
Vallisa, Daniele
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
GIMEMA, NCT04722848 / 2020-006048-15: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Recruiting
3
236
Europe
Ponatinib + Blinatumomab, Chemotherapy + Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Amgen S.r.l. via E. Tazzoli, 6 - 20154 - Milano, Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges, Switzerland
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
09/27
09/27
NCT02371161 / 2013-003256-20: Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Recruiting
2
135
Europe
R-DHAP/R-ICE, R-DHAP or R-ICE and BEAM or FEAM
Fondazione Italiana Linfomi ONLUS
Non Hodgkin Lymphoma
12/18
02/23
GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Completed
2
78
Europe
GvHD prophylaxis
Gruppo Italiano Trapianto di Midollo Osseo
Myeloid Malignancies
11/22
11/22
PENTALLO, NCT03494959: Pentaglobin in CRE and PA Neutropenic Infections

Active, not recruiting
2
120
Europe
Pentaglobin
Gruppo Italiano Trapianto di Midollo Osseo
Septic Shock
05/24
05/25
NCT05306301 / 2022-000633-17: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Active, not recruiting
N/A
75
Europe
Immunogenic profile
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Acute Myeloid Leukemia
12/24
12/25
AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting
N/A
100
Europe
Functional tests, Next Generation Sequencing analysis, Microvesicles analysis
Azienda Ospedaliero-Universitaria di Parma
Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic
03/25
03/25
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
NCT05694325: Biologic Characterization of Patients With ITP

Recruiting
N/A
200
Europe
peripheral blood and bone marrow withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
Immune Thrombocytopenia
11/26
11/26
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
Trabacchi, Elena
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
Bosi, Costanza
PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera

Completed
N/A
1150
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Polycythemia Vera
12/23
12/23
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruiting
N/A
1055
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
05/32
05/32
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23

Download Options